Aflibercept

Aflibercept has been studied in 7 papers since 2018: 1 trial and 2 observational studies in people, 1 in animals, 2 in cells, 1 review; 2 in the past year. It is an approved medicine. The newest paper, Mar 26, 2026: “Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction”.

InterventionApproved 2011

7 papers study it5 findingsUpdated

MeSH

See all 7 papers on aflibercept

At a glance

The findings reach people, from one lab or study. 4 independent labs in 4 countries; 203 trials, none about aging, 55 with no results posted.

“aflibercept: adjusted RR 0.82; 95% CI 0.65-1.04; P = 0.10”
Myocardial Infarction, Stroke, and Death after Intravitreal Injection of Anti-VEGF in a Nationwide StudyOphthalmology science2026doi:10.1016/j.xops.2026.101104

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 4 independent labs in 4 countries
  • 203 trials, none about aging, 55 with no results posted
  • Funders: National Research Foundation of Korea and 4 more
  • 2 of 5 findings with company ties
  • 3 of 203 trials sponsored by its developers
  • Human trial1
  • Humans2
  • Animals1
  • Cells2

What did studies of aflibercept find?

5

Studies of aflibercept measured 5 outcomes, among them myocardial infarction, stroke, or death, choroidal neovascularization and cellular senescence.

Myocardial infarction, stroke, or death

no changein humans1RR 0.82

1 study
  1. Aflibercept was not clearly linked with myocardial infarction, stroke, or death in humans (subgroup analysis by agent used for first anti-VEGF IVT) (adjusted RR 0.82; 95% CI 0.65-1.04; P = 0.10).

    Humanssubgroup analysis by agent used for first anti-VEGF IVT28 days

Choroidal neovascularization

downin mice1

1 study
  1. Aflibercept decreases choroidal neovascularization in mice (laser-induced CNV).

    Animalslaser-induced CNV

More on Choroidal neovascularization

Cellular senescence

no changein human cells1

1 study
  1. Aflibercept showed no clear effect on cellular senescence in human cells (senescent hiPSC-derived RPE cells).

    Cellssenescent hiPSC-derived RPE cellsretinal pigment epithelial cellsclinical dose3 days

More on Cellular senescence

Cell viability

no changein human cells1

1 study
  1. Aflibercept showed no clear effect on cell viability in human cells (senescent hiPSC-derived RPE cells).

    Cellssenescent hiPSC-derived RPE cellsretinal pigment epithelial cellsclinical dose3 days

Beta-galactosidase

downin pig cells1

1 study
  1. Aflibercept decreases beta-galactosidase in pig cells after 1 day and after 12 weeks (p<0.01 at 1 day, p<0.05 at 12 weeks).

    Cellsafter 1 day and after 12 weeksretinal pigment epithelial cells125 μg/ml1 day and 12 weeks

More on Beta-galactosidase

Has aflibercept been tested in people?

0 of 203 about aging

Yes: 1 trial and 2 observational studies in people have been published, and 198 trials are registered.

Approved

  • FDA Eylea

    Nov 18, 2011Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Retinopathy of Prematurity, Diabetic Macular Edema, neovascular age-related macular degeneration

  • EMA Eylea

    Nov 21, 2012Wet Macular Degeneration, Macular Edema, Retinal Vein Occlusion, Choroidal Neovascularization, Retinopathy of Prematurity, Diabetic Macular Oedema, Macular Oedema, visual impairment, neovascular age-related macular degeneration

  • EMA Zaltrap

    Feb 1, 2013Colorectal Neoplasms, Metastatic Colorectal Cancer

  • FDA Eylea HD

    Aug 18, 2023Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Diabetic Macular Edema, neovascular age-related macular degeneration

  • EMA Yesafili

    Sep 15, 2023Macular Edema, Retinal Vein Occlusion, Diabetic Retinopathy, Myopia, Degenerative, Diabetic Macular Oedema, Macular Oedema, visual impairment, neovascular age-related macular degeneration

  • FDA Yesafili

    May 20, 2024Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Diabetic Macular Edema, neovascular age-related macular degeneration

All 21

Repurposing

40 of 63

In trials

  • Pathologic Neovascularization

    Phase 4Status unknown4 trials

  • Chorioretinal vascular diseases

    Phase 4Results posted2 trials

  • Colorectal cancer metastatic

    Phase 3Results posted3 trials

  • Center-involved diabetic macular edema

    Phase 3Completed1 trial

  • Macular edema secondary to retinal vein occlusion

    Phase 3Results posted1 trial

  • nAMD

    Phase 3Recruiting1 trial

All 16

Stopped

  • NCT02002377TerminatedMacular degeneration

    Inadequate enrollment due to investigational product becoming newly available on the Canadian market soon after study start

  • NCT05473715TerminatedMacular degeneration

    Study terminated due to administrative reasons not related to efficacy or safety.

  • NCT00574275TerminatedPancreatic neoplasms

    Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival

  • NCT00509249TerminatedLeukemia, Myelomonocytic, Chronic

    Early termination for discouraging results

  • NCT00437034TerminatedMultiple myeloma

    Poor accrual

  • NCT02797704TerminatedCorneal neovascularization

    the treatment was found to be inefficient for all recruited patients

All 7

Who is developing aflibercept?

3 companies: Bayer, Merck Sharp & Dohme and Regeneron Pharmaceuticals.

Companies
  • BayerPhase 4diabetic macular edema, neovascular age-related macular degeneration
  • Merck Sharp & DohmePhase 3diabetic macular edema, retinal vein occlusion
  • Regeneron PharmaceuticalsPhase 3neovascular age-related macular degeneration, diabetic macular edema

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months